Utah Medical Products opened higher at $73.40, compared with its previous close of $73.03. In the last trading session, the stock traded between $73.25 and $73.91. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Utah Medical Products is now worth
$ 69.98
Resulting in a loss of
$ 30.02 (30.02%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
+$0.76 (+1.04%)
Day High
$73.91
Day Low
$73.25
Day Open
$73.40
Prev Close
$73.03
Volume
10,310
1W Return
1.85%
1M Return
-1.05%
3M Return
2.58%
6M Return
15.30%
1Y Return
28.98%
Fundamentals
Market Cap ($ Mn)
210
PE Ratio
22.24
PB Ratio
1.90
PEG Ratio
7.49
ROE
9.57%
ROCE
11.87%
EPS (TTM)
$0.84
Investment Returns
1 Week
1.85%
1 Month
-1.05%
3 Months
2.58%
6 Months
15.30%
9 Months
14.94%
Financials
Quarterly
All values in $ Mn
9.7
Mar 25
10.0
Jun 25
9.8
Sep 25
9.0
Dec 25
8.7
Mar 26
8.5
Jun 26
Updates
22Oct
Utah Medical Products Q3 Results: EPS up 7% YoY, sales down 12%
Utah Medical Products reported Q3 EPS of $0.88, up 7.32% YoY. Sales declined 12.14% YoY to $8.621 million. Revenue fell from $9.812 million in the prior year quarter. EPS increased despite a double-digit drop in sales.
21 days ago
25Sep
Utah Medical Products corrects tender offer expiration to Wednesday
Utah Medical Products corrected the tender offer expiration date to Wednesday, October 7. The error in previous announcements stated the deadline was Tuesday, October 7. The offer to buy 650,000 shares at $75.00 remains unchanged despite the date correction. Company apologized for confusion caused by the incorrect day-of-week listing.
1mo ago
31Aug
Femcare acquires UK firm Orion Medical Supplies for £3.6 million
Femcare Ltd acquires Orion Medical Supplies Ltd for £3.6 million in cash. Deal adds estimated $6 million to Utah Medical Products' annual consolidated sales. Operations will move to Femcare's Romsey facilities to dilute overhead expenses. Orion specializes in harm reduction medical devices for UK and European markets. Risk factors to be detailed in Q3FY26 SEC 10-Q filing by October 15.
